Phase II trial of D-Trp-6-LH-RH in advanced breast cancer

Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients

“…Indeed, the chronic administration of these drugs produces a persistent reduction in estradiol to levels in the range of postmenopausal values [10]. The safety and clinical ecacy of treatment with LH-RH analogues has been demonstrated by a number of individual studies [4,9,11,12,14,20]. Moreover, the ecacy of these drugs has been shown to be comparable with that of oophorectomy or ovarian irradiation, with side eects being similar and without any major morbidity [3,19].…”